Tocilizumab (TOC) is presumed to be an effective and safe treatment for severe COVID-19,
but its usefulness has not been yet investigated for different SARS-CoV-2 variants. This …

To assess tocilizumab (TCZ) efficacy associated to standard of care (SOC) compared to
SOC alone in severe coronavirus associated disease 2019 (COVID-19) patients. In a …

Background SARS-CoV-2 is associated with a severe inflammatory response contributing to
respiratory and systemic manifestations, morbidity, and mortality in patients with coronavirus …

Background We aimed to determine the impact of tocilizumab use on severe COVID-19
(coronavirus disease 19) pneumonia mortality. Methods We performed a multicentre …

The novel coronavirus disease 2019 (COVID-19) worldwide pandemic has placed a
significant burden on hospitals and healthcare providers. The immune response to this …

Background Controversy remains about the efficacy of tocilizumab (TCZ) for the treatment of
severe COVID-19. We aimed to analyze the profile of TCZ-respondent patients. Methods We …

Background Cytokine release syndrome (CRS), characterized by overproduction of
proinflammatory cytokines in the course of severe coronavirus disease 2019 (COVID-19) …

Objectives Tocilizumab has been proposed as a candidate therapy for patients with severe
coronavirus disease 2019 (COVID-19), especially among those with higher systemic …

Objective To determine whether tocilizumab improves clinical outcomes for patients with
severe or critical coronavirus disease 2019 (covid-19). Design Randomised, open label trial …

Introduction As the pandemic progresses, the pathophysiology of COVID-19 is becoming
more apparent, and the potential for tocilizumab is increasing. However, the clinical efficacy …